News Agency
Men's Weekly

PADCEV™ (enfortumab vedotin) treatment for Locally Advanced or Metastatic Urothelial Cancer receives market authorisation in Singapore

  • Written by Media Outreach

Enfortumab vedotin is the first antibody drug conjugate approved in Singapore for la/mUC patients who received a prior platinum-containing chemotherapy and a PD-1/L1 inhibitor.

SINGAPORE - Media OutReach - 6 June 2022- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that PADCEV (enfortu...

Read more: PADCEV™ (enfortumab vedotin) treatment for Locally Advanced or Metastatic Urothelial Cancer...

How Signage Shapes Business Visibility And Customer Perception

In today’s competitive commercial environment, signage is far more than just a display element—it acts as a silent communicator between a business and its audience. Whether positioned outdoors or within a retail or corporate space, it provides immediate information about what... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion